Deal Announcements

Endocyte Accepts $26 Million Venture Capital Funding

Tuesday, October 20, 2009 5:51:00 AM PDT | VentureDeal Staff

West Lafayette, Indiana  --  Biotechnology company Endocyte has secured $26 million in its third round of venture capital investment.

Endocyte is developing what it calls receptor targeted therapeutics for the treatment of cancer and other autoimmune diseases.

Investors in the round included Clarion Health Ventures, Sanderling Ventures, Burrill & Co., American Bailey Ventures, Triathlon Medical Ventures and Blue Chip Venture Company.

Email Page  Email Page | Print Page Print Page

Free Trial

Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?

Start your Free 14 Day Trial now – no obligation or credit card required.

Free 14 day trial. No Obligation. Click to Register.
Venturedeal Twitter Venturedeal Facebook Venturedeal Linkedin

PCI - Level1